Use of privacy-preserving record linkage to examine the dispensing of pharmaceutical benefits scheme medicines to pregnant women in Western Australia.
drug dispensing
medicines
pharmacovigilance
pregnancy
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
10
05
2024
received:
27
10
2023
accepted:
13
05
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
ppublish
Résumé
Medications are commonly used during pregnancy to manage pre-existing conditions and conditions that arise during pregnancy. However, not all medications are safe to use in pregnancy. This study utilized privacy-preserving record linkage (PPRL) to examine medications dispensed under the national Pharmaceutical Benefits Scheme (PBS) to pregnant women in Western Australia (WA) overall and by medication safety category. In this retrospective, cross-sectional, population-based study, state perinatal records (Midwives Notification Scheme) were linked with national PBS dispensing data using PPRL. Live and stillborn neonates born between 2012 and 2019 in WA were included. The proportion of pregnancies during which the mother was dispensed a PBS medication was calculated, overall and by medication safety category. Factors associated with PBS medication dispensing were examined using logistic regression. PPRL linkage identified matching records for 97.4% of women with perinatal records. A total of 271 739 pregnancies were identified, with 158 585 (58.4%) pregnancies involving the dispensing of at least one PBS medication. Category A medications (those considered safe in pregnancy) were the most commonly dispensed (n = 119 126, 43.8%) followed by B3 (n = 51 135, 18.8%) and B1 (n = 42 388, 15.6%) medication (those with unknown safety). Over the study period, the dispensing of PBS medications in pregnancy increased (OR: 1.06, 95%CI: 1.06, 1.07). The strongest predictor of medication dispensing in pregnancy was pre-pregnancy dispensing (OR: 3.61, 95%CI: 3.54, 3.68). Other factors associated with medication use in pregnancy were smoking, older maternal age, obesity, and prior pregnancies. Privacy preserving record linkage provides a way to link cross-jurisdictional data while preserving patient confidentiality and data security. The dispensing of PBS medication in pregnancy was common and increased over time, with approximately 60% of women dispensed at least one medication during pregnancy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e5845Informations de copyright
© 2024 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.
Références
Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43(8):487‐514.
Sinclair SM, Miller RK, Chambers C, Cooper EM. Medication safety during pregnancy: improving evidence‐based practice. J Midwifery Womens Health. 2016;61(1):52‐67.
Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157C(3):175‐182.
TGA. Prescribing medicines in pregnancy database. 2023 https://www.tga.gov.au/products/medicines/find-information-about-medicine/prescribing-medicines-pregnancy-database#database-search
Havard A, Barbieri S, Hanly M, et al. Medications used disproportionately during pregnancy: priorities for research on the risks and benefits of medications when used during pregnancy. Pharmacoepidemiol Drug Saf. 2021;30(1):53‐64.
Benevent J, Montastruc F, Damase‐Michel C. The importance of pharmacoepidemiology in pregnancy‐implications for safety. Expert Opin Drug Saf. 2017;16(10):1181‐1190.
de Oliveira Costa J, Bruno C, Schaffer AL, Raichand S, Karanges EA, Pearson SA. The changing face of Australian data reforms: impact on pharmacoepidemiology research. Int J Popul Data Sci. 2021;6(1):1418.
Randall SM, Ferrante AM, Boyd JH, Bauer JK, Semmens JB. Privacy‐preserving record linkage on large real world datasets. J Biomed Inform. 2014;50:205‐212.
Randall S, Wichmann H, Brown A, et al. A blinded evaluation of privacy preserving record linkage with bloom filters. BMC Med Res Methodol. 2022;22(1):22.
TGA. Australian categorisation system for prescribing medicines in pregnancy. 2011 https://www.tga.gov.au/australian-categorisation-system-prescribing-medicines-pregnancy
Mellish L, Karanges EA, Litchfield MJ, et al. The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Res Notes. 2015;8(1):634.
PBS expenditure and prescriptions report 1 July 2019 to 30 June 2020 A.G.D.O. Health, Editor: Canberra. 2020.
TGA. Pharmaceutical benefits: Fees, patient contributions and safety net thresholds. 2023 https://www.pbs.gov.au/info/healthpro/explanatory-notes/front/fee
Anon. MIMS Online, MIMS Australia. 2024.
Randall SM, Brown AP, Ferrante AM, Boyd JH. Privacy preserving linkage using multiple match‐keys. Int J Popul Data Sci. 2019;4(1):1094.
Boyd JH, Randall SM, Brown AP, et al. Population data centre profiles: Centre for data linkage. Int J Popul Data Sci. 2020;4(2):1139.
Wise P, Williamson C. Building on SEIFA: finer levels of socio‐economic summary measures, A.B.O. Statistics, Editor: Canberra. 2013.
Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: a cross‐sectional, multinational web‐based study. BMJ Open. 2014;4(2):e004365.
Jackson H, Grzeskowiak LE, Enticott J, Callander E. Pharmacoepidemiology and costs of medications dispensed during pregnancy: a retrospective population‐based study. BJOG. 2023;130:1317‐1327.
Donald S, Sharples K, Barson D, Horsburgh S, Parkin L. Patterns of prescription medicine dispensing before and during pregnancy in New Zealand, 2005‐2015. PLoS One. 2020;15(6):e0234153.
Smolina K, Hanley GE, Mintzes B, Oberlander TF, Morgan S. Trends and determinants of prescription drug use during pregnancy and postpartum in British Columbia, 2002‐2011: a population‐based cohort study. PLoS One. 2015;10(5):e0128312.
Mitchell AA et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976‐2008. Am J Obstet Gynecol. 2011;205(1):51‐e1‐8.
Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2011;20(9):895‐902.
Trønnes JN, Lupattelli A, Nordeng H. Safety profile of medication used during pregnancy: results of a multinational European study. Pharmacoepidemiol Drug Saf. 2017;26(7):802‐811.
Engeland A, Bjørge T, Klungsøyr K, Hjellvik V, Skurtveit S, Furu K. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiol Drug Saf. 2018;27(9):995‐1004.
Subramanian A, Azcoaga‐Lorenzo A, Anand A, et al. Polypharmacy during pregnancy and associated risk factors: a retrospective analysis of 577 medication exposures among 1.5 million pregnancies in the UK, 2000‐2019. BMC Med. 2023;21(1):21.
Roelands J, Jamison MG, Lyerly AD, James AH. Consequences of smoking during pregnancy on maternal health. J Womens Health (Larchmt). 2009;18(6):867‐872.
Davies GAL, Maxwell C, McLeod L, et al. Obesity in pregnancy. J Obstet Gynaecol Can. 2010;32(2):165‐173.
Goyal S, Kortsmit K, Cox S, et al. Prevalence of home births and associated risk profile and maternal characteristics, 2016‐2018. Obstet Gynecol. 2020;136(6):1195‐1203.
Eliner Y, Gulersen M, Kasar A, et al. Maternal and neonatal complications in teen pregnancies: a comprehensive study of 661,062 patients. J Adolesc Health. 2022;70(6):922‐927.
Anon. PBS expenditure and prescriptions report 1 July 2020 to 30 June 2021, D.O. Health, Editor. Australian Government: Canberra. 2022.